Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 12.41% is 284% above its 5-year average of -6.73%, near the high end of its 5-year range (-35.95%–12.79%).
475.49% above its 12-month average of -3.30%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-28): 3.11%.
RETURN ON ASSETS (ROA)
12.41%
RETURN ON ASSETS (ROA) AVG TTM
-3.30%
RETURN ON ASSETS (ROA) AVG 3Y
-13.51%
RETURN ON ASSETS (ROA) AVG 5Y
-6.73%
RETURN ON ASSETS (ROA) AVG 10Y
2.03%
RETURN ON ASSETS (ROA) AVG 15Y
9.27%
RETURN ON ASSETS (ROA) AVG 20Y
8.91%
CURRENT VS TTM AVG
+475.49%
CURRENT VS 3Y AVG
+191.86%
CURRENT VS 5Y AVG
+284.40%
CURRENT VS 10Y AVG
+511.33%
CURRENT VS 15Y AVG
+33.85%
CURRENT VS 20Y AVG
+39.29%
SECTOR MEDIAN · HEALTHCARE
4.94%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+151.21%
vs the sector median at left
Illumina, Inc.
Market Cap
$41.31B
Return on Assets (ROA)
12.41%
TTM Avg
-3.30%
3Y Avg
-13.51%
5Y Avg
-6.73%
Market Cap
$40.89B
Return on Assets (ROA)
33.11%
TTM Avg
29.29%
3Y Avg
27.30%
5Y Avg
27.52%
Market Cap
$41.75B
Return on Assets (ROA)
0.67%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$42.50B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$46.04B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$47.38B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
Market Cap
$48.72B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$49.03B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Illumina, Inc. (ILMN) | $41.31B | 12.41% | -3.30% | -13.51% | -6.73% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.89B | 33.11% | 29.29% | 27.30% | 27.52% |
| Waters Corporation (WAT)vs › | $41.75B | 0.67% | 13.34% | 15.53% | 17.15% |
| IQVIA Holdings Inc. (IQV)vs › | $42.50B | 4.60% | 4.82% | 4.76% | 4.01% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $46.04B | 1.77% | -0.35% | -1.89% | -2.43% |
| Humana Inc. (HUM)vs › | $46.63B | 2.23% | 2.52% | 4.20% | 5.49% |
| Agilent Technologies, Inc. (A)vs › | $47.38B | 10.31% | 10.56% | 11.14% | 10.55% |
| Becton, Dickinson and Company (BDX)vs › | $48.72B | 1.85% | 3.00% | 3.04% | 2.95% |
| Edwards Lifesciences Corporation (EW)vs › | $49.03B | 7.25% | 19.91% | 18.29% | 17.04% |
| Biogen Inc. (BIIB)vs › | $32.49B | 2.60% | 5.11% | 6.74% | 8.29% |
ROA
12.4%
ROE
29.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-28 | 12.79% |
| 2024-12-29 | -19.40% |
| 2023-12-31 | -11.48% |
| 2023-01-01 | -35.95% |
| 2022-01-02 | 5.01% |
| 2021-01-03 | 8.65% |
| 2019-12-29 | 13.70% |
| 2018-12-31 | 11.87% |
| 2017-12-31 | 13.81% |
| 2016-12-31 | 10.81% |
| 2015-12-31 | 12.52% |
| 2014-12-31 | 10.59% |
| 2013-12-31 | 4.15% |
| 2012-12-31 | 5.89% |
| 2011-12-31 | 3.95% |
| 2010-12-31 | 6.79% |
| 2009-12-31 | 5.05% |
| 2008-12-31 | 3.67% |
| 2007-12-31 | -28.18% |
| 2006-12-31 | 13.30% |
| 2005-12-31 | -20.75% |
| 2004-12-31 | -6.56% |
| 2003-12-31 | -27.27% |
| 2002-12-31 | -33.08% |
| 2001-12-31 | -20.27% |
| 2000-12-31 | -14.01% |
| 1999-12-31 | -16.28% |
